Estimates of Japanese Encephalitis mortality and morbidity: A systematic review and modeling analysis

Yuwei Cheng, Nhat Tran Minh, Quan Tran Minh, Shreya Khandelwal, Hannah E. Clapham

1 Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore, 2 Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam, 3 Biological Sciences Department, University of Notre Dame, Notre Dame, Indiana, United States of America

* hannah.clapham@nus.edu.sg

Abstract

Background

Japanese Encephalitis (JE) is known for its high case fatality ratio (CFR) and long-term neurological sequelae. Over the years, efforts in JE treatment and control might change the JE fatality risk. However, previous estimates were from 10 years ago, using data from cases in the 10 years before this. Estimating JE disease severity is challenging because data come from countries with different JE surveillance systems, diagnostic methods, and study designs. Without precise and timely JE disease severity estimates, there is continued uncertainty about the JE disease burden and the effect of JE vaccination.

Methodology

We performed a systematic review to collate age-stratified JE fatality and morbidity data. We used a stepwise model selection with BIC as the selection criteria to identify JE CFR drivers. We used stacked regression, to predict country-specific JE CFR from 1961 to 2030. JE morbidity estimates were grouped from similar study designs to estimate the proportion of JE survivors with long-term neurological sequelae.

Principal findings

We included 82 and 50 peer-reviewed journal articles published as of March 06 2021 for JE fatality and morbidity with 22 articles in both analyses. Results suggested overall JE CFR estimates of 26% (95% CI 22, 30) in 1961–1979, 20% (95% CI 17, 24) in 1980–1999, 14% (95% CI 11, 17) in 2000–2018, and 14% (95% CI 11, 17) in 2019–2030. Holding other variables constant, we found that JE fatality risk decreased over time (OR: 0.965; 95% CI: 0.947–0.983). Younger JE cases had a slightly higher JE fatality risk (OR: 1.012; 95% CI: 1.003–1.021). The odds of JE fatality in countries with JE vaccination is 0.802 (90% CI: 0.653–0.994; 95% CI: 0.62–1.033) times lower than the odds in countries without JE vaccination. Ten percentage increase in the percentage of rural population to the total population was associated with 15.35% (95% CI: 7.71, 22.57) decrease in JE fatality odds. Ten
percentage increase in population growth rate is associated with 3.71% (90% CI: 0.23, 7.18; 95% CI: -0.4, 8.15) increase in JE fatality odds. Adjusting for the effect of year, rural population percent, age of JE cases, and population growth rate, we estimated that there was a higher odds of JE fatality in India compared to China. (OR: 5.46, 95% CI: 3.61–8.31). Using the prediction model we found that, in 2000–2018, Brunei, Pakistan, and Timor-Leste were predicted to have the highest JE CFR of 20%. Bangladesh, Guam, Pakistan, Philippines, and Vietnam had projected JE CFR over 20% for after 2018, whereas the projected JE CFRs were below 10% in China, Indonesia, Cambodia, Myanmar, Malaysia, and Thailand.

For disability, we estimated that 36% (min-max 0–85) JE patients recovered fully at hospital discharge. One year after hospital discharge, 46% (min-max 0%-97%) JE survivors were estimated to live normally but 49% (min-max 3% - 86%) still had neurological sequelae.

**Conclusion**

JE CFR estimates were lower than 20% after 2000. Our study provides an updated estimation of CFR and proportion of JE cases with long-term neurological sequelae that could help to refine cost-benefit assessment for JE control and elimination programs.
risk for JE infection [2]. The global mortality burden of JE was estimated to be 25 thousand deaths [4] in 2015, and 20 thousand in 2011 [5]. JE associated DALYs lost were estimated to be 3161, 3022, 1412, and 1012 in Thailand, China, Vietnam, and Indonesia [6]. In these four countries, 58%-70% of DALYs lost were due to post-JE disability.

To evaluate JE disease burden, the estimates of case-fatality ratio (CFR) computed as the proportion of reported JE cases that die and long-term morbidity ratio computed as the proportion of JE patients that had life-long neurological sequelae were crucial. JE CFR estimates ranging from 20% to 30% and long-term morbidity rates ranging from 30% to 50% were used by most JE disease burden models [3, 4, 6]. The range of JE CFR estimates was derived in 2008 based on 13 studies [7–19] covering 8 JE endemic countries and areas including Bangladesh, India, Japan, Korea, Nepal, Taiwan, Thailand, and Vietnam. Likewise, 14 studies [7, 12, 17, 18, 20–29] encompassing China, India, Vietnam, and Thailand were selected to construct long-term JE morbidity rates.

Despite large variations observed in JE CFRs across time and space, currently there is no available country-specific CFR estimates for accurate mortality burden estimation. Reported JE CFRs were as low as 0% in Thailand in 1972 [30], in Korea in 1982 [31], in Japan in 1994 [32], in India in 2004 [33], and in Myanmar in 2013 [34]. Reported JE CFRs were as high as 100% in Korea and India (estimates ranging from 1962–2006 [8, 31, 33, 35–37]).

JE fatality risk might change as the characteristics of JE susceptible populations evolve with the strengthened surveillance system [38, 39], expanded immunization coverage [38], increased age of infection [38–41], advanced case confirmation methods [42, 43], and improved healthcare. Even though there is no effective treatment to cure the disease [44], multiple types of JE vaccine including inactivated vaccine, live attenuated vaccine, and chimeric vaccine, targeting different JE strains and phenotypes, were developed for the purpose of better disease control [45]. As of 2016, 13 out of 24 JE endemic countries had implemented JE immunization program, nationally or sub-nationally. The proportion of JE endemic countries that conducted JE surveillance and routinely tested JE cases has increased from 21% (5/24) in 2012 to 92% (22/24) in 2016 [38, 39].

Time-series analysis in China and India showed a decreasing pattern in JE CFR [46, 47]. However, there have not been any updates in the estimated values for JE CFR estimates. Although the estimate of long-term morbidity ratio for JE is available, it is not stratified by the severity level and derived from studies published two decades ago. In addition, it was not clear how the estimate was constructed [48]. Without precise and timely estimates of JE fatality and long-term morbidity, there is continued uncertainty about the JE disease burden and the effect of JE vaccination.

Therefore, in this paper we updated the JE mortality and morbidity estimates with data collated from a systematic review and built models to estimate the CFR for countries and time periods which we do not have data.

**Methodology**

**Case fatality**

We conducted a systematic review of JE case fatality; we used the search terms “fatality” or “mortality” or “lethal” or “death” in all fields with “Japanese encephalitis” in the title or abstract to find all available articles in PubMed. We screened all titles and abstracts. For those with age-stratified case-fatality data, we retrieved the full-texts, and the articles were read by two independent reviewers. If abstracts were not available, full-texts articles were assessed and examined by the two independent researchers (S1 Checklist). We included articles in English with data on CFR of JE infections in humans after 1960 when more than 20 JE cases and 1 JE death...
are reported. Thus, we removed articles that were studies on vaccine impact evaluation, cost-benefit analysis of the JE immunization program, and biological studies that focused on molecular research. Studies that were not written in English, studies that were not on humans, studies with no case-fatality data, and studies that had duplicated data resources from another included paper were also excluded. For each study we extracted the number of cases, deaths, and computed case-fatality rate as the ratio between deaths and confirmed cases for JE overall, by year, and by age where possible. This subgrouping constitutes a JE CFR record. Information on catchment areas for the study, case confirmation methods, regional vaccination programs, outbreaks, and the type of surveillance systems which collected and reported the JE cases were also collected. For country-level socioeconomic variables potentially correlated to JE CFR, we collected population density, GDP growth rate, GDP per capita, under-5 mortality rate, population growth rate, percentage of rural population in total population, and urban population size from the World Bank Open Data [49] (S1 Table).

As co-variate data was available for 20 of the endemic countries, we included 20 countries in our analysis (Bangladesh, Brunei, Cambodia, China, Guam, India, Indonesia, Japan, Laos PDR, Malaysia, Myanmar, Nepal, Pakistan, Papua New Guinea, Philippines, South Korea, Sri Lanka, Thailand, Timor-Leste and Vietnam).

To identify variables associated with variation in JE CFR (inference model), we made inference using generalized linear regression. This analysis was conducted for all 20 endemic countries. We included Year, Length of Study, Age Lower (Minimum age of the reported JE patients), Age Upper (Maximum age of the reported JE patients), JE cases, deaths, JE diagnostic method, Type of Surveillance System, Geographical location, Outbreak (1, if the study was conducted during an outbreak), Youth (if the study was conducted among individuals less than 18 years of age), Vaccination (whether the country has a vaccination program), GDP per capita and annual growth rate, Under 5 mortality rate, Population Growth, Population Density, Rural population (as a % of total population) a Urban Population (in millions).

We used the logit-transformed CFR as the response variable to fit the model using the above covariates. The best model with the lowest BIC was selected by stepwise model selection.

**Model formula for the selected model:**

\[
\log \left( \frac{CFR}{1 - CFR} \right) = \beta_0 + \beta_1 \text{AgeLower} + \beta_2 \text{Year} + \beta_3 \log(\text{Population growth}) + \beta_4 \log(\text{Rural Population (\%))} \\
+ \beta_5 \text{Vaccination} + \sum_{i=1}^{c} \beta_i \text{i}_{f}\text{T}_{i-c}
\]

(S1 File). We checked for normal assumption of residual distribution. We also checked for influential points.

After using the inference model to identify the JE CFR drivers, we then used six models to project the CFR for endemic places from 1961 to 2018: 1) LASSO, 2) Principal Component Regression (PCR), 3) Gradient Boosting Machine (GBM), 4) Neural Network (NN), 5) Multiple Linear Regression (MLR), and 6) a weighting-based algorithm separately to stack CFR predictions from the base learners (the base learners are models 1–4). The prediction error is most likely to reduce when the stacked base learners are uncorrelated and have high variability.

We used the variables identified from the inference model population density, GDP annual growth rate, under-5 mortality, GDP per capita, population growth rate, percentage of rural
population in total population, urban population size, diagnostic method (fixed as WHO’s JE case definition: JE IgM antibody in CSF or serum as confirmed by MAC-ELISA on patients with acute encephalitis syndrome), type of surveillance system (fixed as national surveillance), and regional vaccination status as predictors. Using the prediction model, estimates were calculated the CFR for 1961–1979, 1980–1999 and for 2000–2018. Due to lack of availability of socioeconomic data required for the model we exclude 6 (Myanmar, Cambodia, Vietnam, Timor-Leste, Laos and Guam) out of 20 endemic countries for the years 1961–1979; 3 countries (Guam, Myanmar, and Timor-Leste) for the years 1980–1999 and Guam for 2000–2018. We calculated the binomial log likelihood of these predictions across all data points (S1 File).

We also use this model (model 6) to project the CFR for future years post 2018. For this projection model, we assumed that the JE immunization status remains unchanged in all the countries for which the model was used. We included all 20 endemic countries for the projection.

We calculated the prediction average for each country and year using this model. We bootstrapped the collated dataset 2000 times.

We conducted a sensitivity analysis for the inference models by excluding data from India or China to evaluate the robustness of our model to these countries from which there was a large amount of data (S7 Table). We also ran the prediction model using the subset of data that had the WHO case definition to assess how this might influence the results.

Disability

For JE disability review, we used the search terms “weakness” or “discharge” or “recover” or “abnormal” or “impair” or “disorder” or “disability” in all fields with “Japanese encephalitis” or “Viral Encephalitis, Japanese” in the title or abstract to find all available articles in PubMed. We screened all titles, abstracts, and articles. We included only studies written in English that reported data on the proportion of JE survivors that develop disability after JE infection. Thus, we excluded studies with JE infection not on humans, studies on irrelevant pathogens, studies with focus on suggestions for traveler’s safety, studies on JE vaccine effectiveness evaluation, studies not in English, studies with no available disability data, and case reports that only examine clinical symptoms and disease development of only one JE patient (S2 Checklist). We extracted JE records that contained information on year of the study, the numbers of reported JE cases, JE fatality, cases with complete recovery, and cases with sequelae, age of the JE patients, outcome measurement time, and disability assessment method, where possible. We estimated the proportion of long-term neurological sequelae by age and depending on the definition of neurological sequelae used in the respective study. We also analyzed the proportion of JE patients who had complete recovery at or after hospital discharge by age, where possible. For papers included in both analyses (CFR and disability), we assessed the relationship between JE CFR and the proportion of neurological sequelae at hospital discharge using a linear regression.

All analyses were conducted by using the R statistical software [50], version 4.0.4.

Results

Mortality

The data collated. On March 06, 2021, we identified 917 studies in the initial literature review (Fig 1). After retrieving and analysing 103 full-text papers, 891 age-stratified JE CFR records were extracted. Due to the unavailability of associated country-level socioeconomic factors which were required for our model predictors, 161 records that from before 1961, or in Taiwan or Northern Mariana Islands were removed. 244 records were removed due to very
few reported cases (less than 20) and 17 records with 0 JE fatality were excluded for the ease of taking logit transformation. Finally, 82 studies from which 469 distinct age and year stratified JE CFR records were collated and included in the analysis (S1 Included Characteristics, data in S2 File).

The total dataset collated using the literature review (Table 1) comprised of 406,818 JE cases and 49,225 JE deaths before the year 2000 with a mean unweighted CFR of 28%. After the year 2000, there were 371,853 cases and 36,889 deaths, with a lower mean CFR of 15%.

Table 1. Table of summary statistics of age-stratified Japanese encephalitis (JE) case-fatality observations obtained from the systematic review. Spatial and temporal distribution of the collected JE cases, deaths, and case-fatality ratios (CFR) were presented. India, Korea, and China were the top three countries with the most observed JE records. Other countries from which records were included are Bangladesh, Cambodia, Hong Kong, Indonesia, Japan, Malaysia, Myanmar, Nepal, Thailand, and Vietnam. The unweighted mean is the mean of the CFR calculated across all records in our dataset for a particular time period and country.

| Factor                          | Total | Reported within 1961–1999 | Reported within 2000–2016 |
|--------------------------------|-------|-------------------------|--------------------------|
|                                |       | India | China | Korea | Others | India | China | Korea | Others |
| Age stratified CFR records (%) | 469   | 124   | 14    | 3.6   | 77     | 16.4  | 67    | 14.2  | 97     | 20.7  | 38    | 8.1   | 46    | 9.8   |
| Number of JE cases (%)         | 778,672 | 77,504 | 277,037 | 35.6 | 10,491 | 1.3 | 41,787 | 5.4 | 123,569 | 15.9 | 234,083 | 30.1 | 78    | 0.01  | 14,123 | 1.8   |
| Number of JE deaths (%)        | 86,114 | 23,390 | 18,219 | 21.1 | 2,874 | 3.3 | 4,742 | 5.5 | 26,035 | 30.2 | 9,515 | 11    | 20    | 0.02  | 1,319 | 1.5   |
| Unweighted mean of JE CFR (%)  | 23.4  | 33.4  | 5.7   | 31.2  | 20.9  | 23.2  | 4.8   | 25.6  | 8.8   |

https://doi.org/10.1371/journal.pntd.0010361.t001
studies which reported JE cases, most of them were reported by the national surveillance system. Sentinel hospital surveillance system was the second largest venue where cases were reported, though these ranged in size from one to several hospitals. The sample size of the reported patients in each study varied considerably, ranging from 20 to 68,427 with a median value of 180. The majority (91%) of analyzed JE cases happened in China or India (Table 1).

There were 41% (192/469) observations in which laboratory confirmation method was reported (Fig 2A). The remaining observations were either diagnosed only based on clinical symptoms or had inadequate information to determine the case confirmation method. For the laboratory-confirmed cases, most observations (146/192) used the WHO case definition: JE IgM antibody in CSF or serum as confirmed by MAC-ELISA on patients with acute encephalitis syndrome. This method was the main diagnostic method in all countries except Bangladesh, where detecting neutralization antibody in CSF or serum was the leading JE case confirmation method (Fig 2A). JE case confirmation by the detection of neutralization antibody in cerebrospinal fluid (CSF) or serum was used less frequently over time (Fig 2B); 24% (46/192) observations confirmed JE cases by JE virus, antigen, or pathogen and neutralization antibody in cerebrospinal fluid (CSF) or serum.

**Exploring variables associated with CFR.** The inference model was used to identify the variables associated with the JE CFR. The best model has a BIC of 1132.67. The BIC of the full model is 1214.08 and the BIC of the null model is 1467.84. The residual diagnostic plot (S1 File), does not show any nonlinear trend and non-constant variance. The plot is also symmetric with respect to 0, thus we did not find any issues in the model fitting.

Holding other variables constant, we found that JE fatality risk decreased over time (OR: 0.965; 95% CI: 0.947–0.983) (Table 2). Younger JE cases were associated with higher JE fatality risk (OR: 1.012; 95% CI: 1.003–1.021). JE fatality risk odds in JE immunized countries is 0.802 (90% CI: 0.653–0.994; 95% CI: 0.62–1.033) times of odds in JE unimmunized countries.
Ten percentage increase in the percentage of rural population to the total population was associated with 15.35% (95% CI: 7.71, 22.57) decrease in JE fatality odds. Ten percentage increase in population growth rate is correlated with 3.71% (90% CI: 0.23, 7.18; 95% CI: -0.4, 8.15) increase in JE fatality odds (Table 2). Adjusting for the effect of year, rural population percent, age of JE cases, and population growth rate, the likelihood of JE fatality risk in India is higher than in China. (OR: 5.46, 95% CI: 3.61–8.31) (Table 2).

In sensitivity analysis, we ran the JE inference model without JE records from China and India one at a time and in both cases we observe that lowest Age of JE patients and population growth (in %) were no longer significant at 5% (S2 Table).

## Predicting for countries without data and into the future.

We use the prediction model to estimate the CFR for countries without data and also to project the CFR for the future years after 2018. We identified that with population density, population growth, GDP per capita, GDP growth rate, under-5 mortality, rural population (%), urban population size, country indicators, vaccination, and diagnostic testing method as predictors, stacking with the weighting algorithm as meta learner (model 6) was the best model for CFR prediction and projection (Table 3). Even though LASSO regression (model 1) had the largest median log likelihood, the distribution of the log likelihood of LASSO (model 1) was heavily left tailed. The performance of LASSO (model 1) in the lower 2.5% quantile was 1000 times worse compared to its performance in the upper 2.5% quantile. On the contrary, the performance of model 6 in the lower 2.5% quantile was less than 10 times worse compared to its performance in the upper 2.5% quantile. The performance of stacking with weighting algorithm as meta learner (model 6) had a smaller variance thus, we chose stacking as the best performance model.

Based on JE CFR estimates and records, and using model 6 we project CFR over time and space, as shown in Fig 3. Using the stacking model with weighting algorithm as meta learner (model 6) and without year as predictor the mean global predicted JE CFR was 26% (95% CI 22, 30) in 1961–1979, 20% (95% CI 17, 24) in 1980–1999, 14% (95% CI 11, 17) in 2000–2018.
and the mean projected JE CFR of 14% (95% CI 11, 17) in 2019–2030 (Table 4). By country, Bangladesh, Lao PDR, and Pakistan had JE CFR above 30% before 2000 and for all countries we estimated a considerable decrease in CFR estimates after 2000 (Fig 4). China, Sri Lanka, Nepal, Thailand, and Vietnam had CFR lower than 10% in 2000–2018. We also estimated the CFR for countries with JEV transmission risk but had for which there were no studies reporting CFR. The estimated JE CFR in 2000–2018 for Brunei was 20%, Sri Lanka 7%, Pakistan 20%, Papua New Guinea 15%, and Timor-Leste 20%. Even though the projected JE CFR in 2019–2030 increased considerably from the previous two decades in Bangladesh and Vietnam (Table 4), the associated confidence intervals were fairly wide, and the projected estimates were not statistically different from the predicted estimate in 2000–2018.

Sensitivity analyses
To understand the impact of the JE case definitions, we ran the model on subset of the data with case definition (WHO case definition). We ran model 6 on JE CFR records with clear case definition. The estimated JE CFR in 1961–1979 was 28% (95% CI: 22, 33), JE CFR in 1980–1999 was 25% (95% CI: 19, 30), JE CFR in 2000–2018 was 18% (95% CI: 14, 23), and JE CFR in 2019–2030 was 14% (95% CI: 12, 17). The decreasing trend in JE CFR estimates is the same here and there are no statistical differences in all estimates compared to the estimates in the main analysis (S3 Table).

To understand if there was still variation in time not captured by our co-variates, we explored including year as a predictor into the prediction model. Model performance based on binomial likelihood after including year as predictor was worse (S4 Table). We did not use year as a predictor as it is not time, but other socioeconomic variables that we include in the model are changing in time that would be influencing the output. We therefore chose to use the model without year.

Morbidity
We identified 2018 articles in the initial literature review (Fig 5). We excluded 1612 studies through title screening as they were not studies on humans, studies on other flaviviruses, or safety suggestions for travelers. We analyzed 360 abstracts and 46 full articles that did not have available abstracts post which 290 articles were removed as they did not contain data on JE disability. We then analyzed full-texts of the remaining 98 studies and 18 abstracts. We excluded 18 abstracts and 19 articles because the disability data are not available. We further excluded

Table 3. Table of binomial log likelihood calculated from 6 models in 2000 bootstrapped datasets sampled from the dataset collated from systematic review. In each bootstrapped dataset we computed binomial log likelihood for each model. For each model summary statistics of the distribution of log likelihood was presented. Abbreviations: LASSO: Least Absolute Shrinkage and Selection Operator; PCR: Principal Component Regression; GBM: Gradient Boosting Machine; NN: Neural Network; MLR: Multiple Linear Regression.

| Model                     | Log likelihood | Predictors | Median     | 95% CI       |
|---------------------------|----------------|------------|------------|--------------|
| 1. LASSO                  | -9034          |            | (-7006221, -7260) |
| 2. PCR                    | -98871         |            | (-293247, -10374)  |
| 3. GBM                    | -24177         |            | (-51047, -11261)  |
| 4. NN                     | -140811        |            | (-2703911, -26363) |
| 5. Stacking (MLR)         | -24799         |            | (-56287, -11407)  |
| 6. Stacking (Weighting algorithm) | -19274   |            | (-73941, -8886)  |

https://doi.org/10.1371/journal.pntd.0010361.t003
24 JE case reports (these reports focus on clinical symptoms and disease prognosis for a single patient, which is not helpful in assessing the proportion of JE survivors that develop long-term disability). We removed 1 editor’s reply, 1 duplicate, and 3 studies that were not in English. Finally, we had a set of 50 articles that led to 76 JE disability records. 22 of these studies were also included in the CFR analysis.

The collated studies covered 14 JE endemic countries and areas including Bangladesh, Cambodia, China, India, Indonesia, Japan, South Korea, Lao PRD, Malaysia, Nepal, Philippines, Taiwan, Thailand, and Vietnam. Most studies were carried out in India (17/50), China (6/50), or Vietnam (6/50). Half of the studies (26/50) analyzed JE cases occurring after 2000. The identified studies had heterogenous follow up times; 22 studies only evaluated the patients’ outcome at hospital discharge and 28 studies evaluated the outcomes at least one month after hospital discharge. Among these 28 studies, 9 studies evaluated the patients’ outcome more than one year after hospital discharge. The study size varied from 4 patients to 144 patients, with 30 as the median study size.

Outcomes of JE patients were evaluated differently across the studies. All studies documented the proportion of JE cases that had neurological deficits. Within these studies, 17
studies documented the type of neurological deficits in detail but did not grade the sequelae severity [20, 24, 26, 28, 51–63]. 33 studies graded the severity of the neurological deficits but adopted a range of evaluation tools. 11 articles categorized the outcome as poor (bedridden), partial (needing help with daily activities), or complete recovery (able to perform daily activities independently)[64–74]. 8 articles used Liverpool Outcome Score (LOS) to assess basic motor and self-care skills and simple cognitive and behavioral functions [75–82]. Patients who were unable to live independently (score 2) were classified as severe. Patients with moderate (score 3) or minor sequelae (score 4) were able to make independent living. 5 articles also grouped patient outcome into severe/moderate/min or yet based on the degree of independent functioning and controllability of seizures or the author’s subjective assessment [17, 83–86]. 4 articles adopted Modified Rankin Scale to measure the degree of disability or dependence in the daily activities [87–90]. 3 articles used Glasgow Coma Scale [91–93] and the remaining 2 articles used the Whitely’s method [94, 95].

On average using all studies definition of “completely recovered” we found 36% (min-max 0–85) of JE patients fully recovered at hospital discharge (S6 Table). For outcome measured more than one year after discharge, 46% (min-max 0–97) of JE survivors had completely recovered. The proportion of children patients (< = 18 years old) with complete recovery was 44% (min-max 9–85), higher than the estimate for adults (23%, min-max 0–67). But there was a wide disparity in adult patients’ outcomes one year after discharge reported by different studies.

Table 4. Table of estimated Japanese encephalitis (JE) case-fatality ratio (CFR) estimated by the stacking model (model 6) without including year as predictor for 20 out of 24 JE endemic countries from 1961 to 2030. Country-specific and year-stratified JE CFRs and their associated 95% CI were presented. Areas with N/A values for JE CFR predictions had at least one unavailable socioeconomic feature.

| JE endemic countries | Case-fatality ratio (95% CI) |
|----------------------|-----------------------------|
|                      | Predicted                   | Projected                  |
|                      | 1961–1979                   | 1980–1999                  | 2000–2018                  | 2019–2030                  |
| Overall              | 26 (21, 31)                 | 20 (17, 24)                | 14 (11, 17)                | 14 (11, 17)                |
| Bangladesh           | 35 (15, 54)                 | 30 (13, 49)                | 18 (8, 35)                 | 28 (10, 51)                |
| Brunei               | 27 (10, 45)                 | 25 (13, 41)                | 20 (10, 34)                | 16 (7, 30)                 |
| China                | 14 (5, 28)                  | 10 (4, 26)                 | 9 (3, 25)                  | 5 (3, 12)                  |
| Guam                 | N/A                         | N/A                        | N/A                        | 24 (15, 37)                |
| Indonesia            | 28 (16, 41)                 | 16 (8, 31)                 | 11 (5, 23)                 | 7 (4, 13)                  |
| India                | 28 (16, 41)                 | 23 (8, 39)                 | 17 (8, 39)                 | 14 (7, 24)                 |
| Japan                | 25 (14, 40)                 | 17 (8, 31)                 | 14 (6, 27)                 | 15 (8, 26)                 |
| Cambodia             | N/A                         | 29 (17, 42)                | 11 (4, 23)                 | 7 (4, 16)                  |
| South Korea          | 24 (13, 37)                 | 24 (14, 36)                | 18 (9, 31)                 | 18 (10, 29)                |
| Lao PDR              | N/A                         | 30 (16, 43)                | 18 (8, 31)                 | 11 (4, 23)                 |
| Sri Lanka            | 14 (7, 21)                  | 6 (4, 10)                  | 7 (3, 17)                  | 10 (4, 21)                 |
| Myanmar              | N/A                         | N/A                        | 14 (7, 27)                 | 6 (3, 21)                  |
| Malaysia             | 21 (11, 35)                 | 21 (12, 36)                | 18 (9, 32)                 | 9 (4, 21)                  |
| Nepal                | 30 (16, 47)                 | 24 (12, 38)                | 7 (2, 15)                  | 10 (5, 21)                 |
| Pakistan             | 36 (23, 49)                 | 34 (20, 49)                | 20 (11, 33)                | 23 (13, 37)                |
| Philippines          | 29 (19, 40)                 | 23 (13, 36)                | 15 (12, 33)                | 22 (12, 36)                |
| Papua New Guinea     | 24 (13, 36)                 | 21 (12, 33)                | 15 (8, 27)                 | 17 (8, 29)                 |
| Thailand             | 26 (14, 40)                 | 12 (7, 21)                 | 5 (3, 11)                  | 4 (3, 9)                   |
| Timor-Leste          | N/A                         | N/A                        | 20 (11, 32)                | 16 (9, 27)                 |
| Vietnam              | N/A                         | 9 (5, 15)                  | 9 (4, 17)                  | 22 (12, 33)                |

https://doi.org/10.1371/journal.pntd.0010361.t004
We further estimated that on average 49% (min-max 5%–95%) of JE patients suffered from some neurological sequelae at hospital discharge compared to a similar estimate, 49% (min-max 3%–86%) when the outcome was measured at least one year after hospital discharge (Fig 6). From studies that graded neurological sequelae severity (33 studies), we further simplified the severity level into two categories, dependent and independent, depending on whether JE patients were able to perform daily activities by themselves. We estimated that 7%–82% JE patients were unable to live independently at discharge (Fig 6). However, the disease severity assessed by different evaluation tools varied significantly. 2 studies that utilized Whitely’s method showed 7%–23% of JE survivors had severe neurological deficits and required assistance to perform daily activities (Fig 7). For another 2 studies that used good/partial/poor as the evaluation metric suggested that 48%–82% of JE patients were either bed-ridden or needing help with daily activities (Fig 7). When the outcome was measured at half a year after hospital discharge, the studies estimated that 3%–75% of patients were unable to live independently (Fig 7).

Within the included follow-up studies, 54% (15/28) studies had patients lost to follow up. Refusal to participate, no contact information, relocation, and leave against medical advice were the top four reasons for the lost to follow up. 7 studies [28, 54, 56, 77, 80, 94, 96] had lost to follow up greater than 20%. Within these articles, 5 studies [28, 54, 56, 77, 80] had follow-up period greater than 1 year, one study [54] alerted refusal to participation due to poor health.
condition may generate bias to the study’s result. Long travel distance and unwillingness to receive medical examination were the main refusal reasons for the rest of studies and might not affect the estimate (S6 Table).

For studies that were included both in the fatality review and disability review, we ran a linear regression to assess whether case-fatality rate during the acute stage was associated with
the proportion of JE patients with neurological sequelae at hospital discharge. As the p value was 0.32 (>0.05), no evidence suggested the existence of linear correlation between the CFR and the proportion of cases with neurological sequelae. (S1 Fig)

**Discussion**

In this paper, we updated JE disease severity estimates using data gathered from the systematic review. We estimated JE CFR in 1961–1979, 1980–1999, 2000–2018, and 2019–2030 of 26%, 20%, 14%, and 14% respectively. We estimated 49% (min-max 3%-86%) JE survivors had long-term neurological sequelae and different recovery patterns between children and adults were observed.

Our CFR estimates before 2000 were consistent with Fischer et al.’s (2008) estimate. Fischer et al. [48] narrowed down the range of JE CFR to 20%-30% by reviewing 13 studies from 8 JE endemic areas published between 1949–2005 [89]. By comprehensively reviewing 82 studies published as of 2021 March 06 from 12 of the JE endemic areas, our study went beyond providing a range of CFR by developing a prediction and projection model to contribute to
understand changes and variation in CFR, the variables that are correlated with CFR, and up-to-date estimates.

Our analysis estimated that the reduced JE CFR estimate was correlated with the expanded coverage of JE immunization (Table 2). JE immunization coverage expanded rapidly after 2000. 67% (10/15) countries and areas introduced the immunization programs nationally or sub-nationally after 2000[42], including China and India where most analyzed JE patients came from. The correlation of JE vaccination with reduced JE CFR would be consistent with vaccination which not only reduced infection, but also moderated the disease severity [45]. Mouse-brained-derived inactivated JE vaccine was showed to be effective in reducing fatality of confirmed cases in 1-14-year-old children by 19.3%[97]. However, it is also possible that the relationship we observe with vaccination is also due to changes in surveillance which were brought with the JE vaccination program [38] or other changes in healthcare that occur concurrently with vaccination, though we did attempt to account for these in the analysis, we could not completely.

Fig 7. Range of Japanese encephalitis (JE) neurological deficits severity level by outcome measurement time and assessment tools. We define dependent as JE survivors who need assistance to perform daily activities and independent as JE patients who can live independently. JE patients with complete recovery show no symptoms of any neurological sequelae. Death measured at least 6 months after hospital discharge excludes death occurred during the acute stage of JE infection. Abbreviations: GPP (Good/Partial/Poor), Liverpool Outcome Score (LOS), Modified Rankin Scale (mRS), SMM (Severe/Moderate/Minor), Glasgow Coma Scale (GCS).

https://doi.org/10.1371/journal.pntd.0010361.g007
In our analysis, we found that population demographics was associated with JE fatality risk and patient’s access to healthcare might be the underlying driver for this correlation. Our result showed that country with higher population growth, denser population, higher proportion of urban population had higher JE fatality risk. In countries that the growth of local healthcare capacity falls behind the population growth rate, patient’s waiting time before getting the treatment might be prolonged, thus worsening the final outcome. Likewise, a populous district or a metropolis is likely to have low individual medical resources, consequently having a negative impact on the fatality rate.

There was minimal information available on the age of cases. We did see a significant, though small, difference in the estimated CFR by age (higher for the studies that included older ages). However, there is information in the way the data from these studies is currently presented. This is an important area of future study as children aged 15 years old and below was the primary targeted population for JE immunization [98], the main age group of the confirmed JE cases in many countries shifted from young children to adults [18, 99, 100]. In countries with childhood JE immunization program, this is something to be aware of, as JE mortality burden in adults might increase with this shifting pattern in the age of infection.

We analyzed country level variation in CFR along with the changes in time. After accounting for the impact of vaccination status, demographic structures, surveillance scales, employed JE diagnostic methods, and other available socioeconomic features, effect of country and time still remained statistically significant (Table 2). Therefore, there are unexplained variations after addressing the current factors and indicated the presence of unobserved features, for instance, improved critical JE case management over time, differences in genotype, differences in healthcare seeking, and heterogenous case-reporting rate which were also crucial in understanding JE CFR variations across time and space.

It was unclear why the projected values from the data in some countries (for example Vietnam, see Fig 3) an increasing trend was observed, which is unusual given the widespread vaccination there. Further analysis would be useful to understand why this is occurring.

Consistent with Fischer et al. (2008)’ estimate that 30%-50% JE survivor had long-term sequelae, our result showed 49% of JE survivors had at least one type of neurological deficits at least one year after at hospital discharge, indicating a permanent damage caused by JE infection. Post-JE disability is the major component of the disease burden and is important to be part of the calculation when assessing whether to include JE vaccination in vaccination programs. However, there was a range of estimates of proportion of cases that experience JE neurological deficits from different studies. This may be due to the inherent differences in the severity of the cases, hospital’s capacity to manage such cases, or the different ranges and focus of the assessment tools used. As well as the disabilities recorded, it was interesting to note that results from two studies presented 20% and 24% JE patients died after hospital discharge, which may mean there is an underestimate of the CFR for JE, however, there was no direct evidence that death was attributed to JE infection.

Our result found that at hospital discharge, a higher proportion (44% min-max: 9–85) of children fully recovered from JE infection compared to adult patients (23% min-max 0–67) (S6 Table). However, one year after hospital discharge, the proportions of children and adult patients who had a complete recovery converged. Patients with different ages may have different disease recovery speeds.

By providing granular risk estimates for JE mortality and morbidity for specific time periods and countries, our study serves as a stepping stone towards improving JE mortality and morbidity estimation, especially for the GAVI burden of disease assessments, including their tracking process toward JE control, elimination, and mortality and morbidity reduction. This is also useful for countries when they are making decisions about the introduction or
continued use of JE vaccination. From a broader perspective, our work proposes a practical framework to estimate country-and-time specific CFR for a disease by using publicly available data. For a disease with large variations in observed CFRs but with only fixed estimates available, our method is more likely to generate precise estimations for disease burdens, which facilitates effective resource channeling and disease control.

In addition to those discussed above relating to specific variables, there were some overall limitations of this analysis. Firstly, our result was constrained by the varying quality of different articles included. Only a few studies screened contained cases and deaths stratified by age thus restricting the analysis by age. The lack of availability of age-stratified data might lead to a biased dataset for model fitting. Several JE cases and deaths collated were aggregated across multiple years. Thus, we were unable to uncover any between year variation in JE CFR and the middle point year was used to index the overall CFR. The accuracy of the projected estimates could be limited by the heterogenous quality of the projected socioeconomic features as well.

Secondly, our model was only able to address across-country variations in JE CFR. Vaccination coverage, healthcare quality and economic development in different regions of a country may vary significantly, resulting within-country variations. Although many studies we screened included catchment areas detailed at province or district level, only country-level socioeconomic features were accessible. Thus, CFR that we gathered were assumed to be nationally representative.

Although 13 countries and areas were included in the modelling, 91% of analyzed JE patients came from China and India. The identified global pattern between CFR and socioeconomic features could be dominated by the results in these two countries. We also excluded records from our analysis that reported 0 JE deaths which may cause an upward bias in our estimates, even though our estimates are lower than the currently available estimate of 20%.

Thirdly, our dataset included records from studies that used multiple methods of JE diagnosis and the heterogeneity across the studies might lead to a biased dataset used in the model construction. We also excluded records from our analysis that reported 0 JE deaths due to inconsistency in the residuals when these were included in the modelling process (Fig D in S1 File). Hence, our estimates may overestimate the CFR and can be considered as an upper bound which is still lower than the current available estimates of JE CFR.

Conclusion

Our analysis enabled us to draw several conclusions. The estimated CFR after 2000 was 14% and it is lower than 20% previously estimated. On average 49% of JE survivors suffered long-term neurological sequelae. The presence of JE immunization program, under-5 mortality, and the age of infection were important predictors to understand spatial-temporal variations in JE CFRs.

Supporting information

S1 Checklist. Case fatality PRISMA checklist.
(DOCX)

S2 Checklist. Disability PRISMA checklist.
(DOCX)

S1 Fig. Scatter plot of proportion of fatality and sequelae at hospital discharge. Dot size was scaled according to the number of patients in the observed records.
(TIF)
S1 Table. Table of detailed description of estimators, predictors, and projectors that were used in the Japanese Encephalitis (JE) case-fatality ratio modelling.

(SDOCX)

S2 Table. Sensitivity analysis: Table of odds ratio of predictors that were used in the regression to fit Japanese encephalitis case-fatality ratio with complete information on age for the inference model without using data from China or India. Mean, Mean (Bootstrap), and 95% confidence interval (CI) of the odds ratio were presented. *** indicates that odds ratio of the factor is different from 1 with a significance level of 95%. Ref stands for reference category.

(SDOCX)

S3 Table. Table of predicted and projected JE case-fatality ratio (CFR) estimated by the stacking model fitted on JE records with clear case definition for 20 out of 24 JE endemic countries from 1961 to 2030. Country-specific and year-stratified JE CFRs and their associated 95% CI were presented.

(SDOCX)

S4 Table. Table of binomial log likelihood calculated from 6 models with year as predictor in 2000 bootstrapped datasets sampled from the dataset collated from systematic review. In each bootstrapped dataset we computed binomial log likelihood for each model. For each model summary statistics of the distribution of log likelihood was presented. Abbreviations: LASSO: Least Absolute Shrinkage and Selection Operator; PCR: Principal Component Regression; GBM: Gradient Boosting Machine; NN: Neural Network; MLR: Multiple Linear Regression.

(SDOCX)

S5 Table. Table of predicted and projected JE case-fatality ratio (CFR) estimated by LASSO fitted on JE records with clear case definition for 20 out of 24 JE endemic countries from 1961 to 2030. Country-specific and year-stratified JE CFRs and their associated 95% CI were presented.

(SDOCX)

S6 Table. Table of dropout analysis.

(SDOCX)

S7 Table. Sensitivity analysis: Tables of predicted and projected CFRs for all countries from 1961–1979, 1980–1999, 2000–2018 using model 6 when fitted without using data from China and India one at a time. Mean CFR, Lower and Upper bounds of the 95% C.I. are presented.

(SDOCX)

S1 File. Detailed methodology description.

(SDOCX)

S2 File. Data.

(XLSX)

S1 Included Characteristics. Table of detailed description of all the records extracted from the studies included in the CFR literature review.

(SDOCX)

Author Contributions

Conceptualization: Hannah E. Clapham.
Data curation: Yuwei Cheng, Nhat Tran Minh.

Formal analysis: Yuwei Cheng.

Funding acquisition: Hannah E. Clapham.

Investigation: Yuwei Cheng.

Methodology: Yuwei Cheng, Hannah E. Clapham.

Project administration: Hannah E. Clapham.

Software: Yuwei Cheng.

Supervision: Hannah E. Clapham.

Visualization: Yuwei Cheng.

Writing – original draft: Yuwei Cheng.

Writing – review & editing: Yuwei Cheng, Nhat Tran Minh, Quan Tran Minh, Shreya Khandelwal, Hannah E. Clapham.

References

1. Solomon T, Ni H, Beasley DWC, Ekkelenkamp M, Cardosa MJ, Barrett ADT. Origin and Evolution of Japanese Encephalitis Virus in Southeast Asia. J Virol. 2003 Mar; 77(5):3091–8. https://doi.org/10.1128/jvi.77.5.3091-3098.2003 PMID: 12584335

2. Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K. Past, present, and future of Japanese encephalitis. Emerg Infect Dis. 2009 Jan; 15(1):1–7. https://doi.org/10.3201/eid1501.080311 PMID: 19116041

3. Hsu YH. Japanese encephalitis. Tzu Chi Med J. 2008; 20(2):154.

4. Quan TM, Thao TTN, Duy NM, Nhat TM, Clapham H. Estimates of the global burden of Japanese encephalitis and the impact of vaccination from 2000–2015. Elife. 2020 May; 9:1–187. https://doi.org/10.7554/eLife.51027 PMID: 32450946

5. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, Ginsburg AS. Systematic reviews 766 Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Heal Organ. 2011; 89:766–74. https://doi.org/10.2471/BLT.10.085233 PMID: 22084515

6. Liu W, Ding D, Clemens JD, Yen NT, Porpil V, Xu Z-Y. Measuring Japanese Encephalitis (JE) Disease Burden in Asia: In: Handbook of Disease Burdens and Quality of Life Measures. Springer New York; 2010. p. 1391–9.

7. Schneider RJ, Firestone MH, Edelman R, Trieu T, Pompibul R. Clinical sequelae after Japanese encephalitis: a one year follow up study in Thailand. Southeast Asian J Trop Med Public Health. 1974; PMID: 4376275

8. Kono R, Kim KH. Comparative epidemiological features of Japanese encephalitis in the Republic of Korea, China (Taiwan) and Japan. Bull World Health Organ. 1969; 40(2):263–77. PMID: 4308334

9. Khan A, AQ K, Dobrzynski L, Ciesielski C, Myat A. A Japanese encephalitis focus in Bangladesh. J Trop Med Hyg. 1981; 84(1):41–44. PMID: 6259374

10. Do OH, Vu TQH, Huynh TKL, Dinh QT, Deubel V. Current situation of Japanese encephalitis in the south of Vietnam, 1976–1992. Vol. 36, Tropical Medicine. 1994. p. 202–14.

11. Burke DS, Lorsomrudee W, Leake CJ, Hoke CH, Nisalak A, Chongswasi V, Laorakpongse T. Fatal outcome in Japanese encephalitis. Am J Trop Med Hyg. 1985; 34(6):1203–10. https://doi.org/10.4269/ajtmh.1985.34.1203 PMID: 3010752

12. Solomon T, Vaughn DW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Vol. 267, Current Topics in Microbiology and Immunology. Curr Top Microbiol Immunol; 2002. p. 171–94. https://doi.org/10.1007/978-3-642-59403-8_9 PMID: 12082989

13. Bista MB, Shrestha JM. Epidemiological situation of Japanese encephalitis in Nepal. Journal of the Nepal Medical Association. 2005. PMID: 16554872
14. GRAYSTON JT, WANG SP, YEN CH. Encephalitis on Taiwan. I. Introduction and epidemiology. Am J Trop Med Hyg. 1962; 11:126–30. https://doi.org/10.4269/ajtmh.1962.11.126 PMID: 13901336

15. Potula R, Badrinath S, Srinivasan S, R P, S B, S S, Potula R, Badrinath S, Srinivasan S. Japanese encephalitis in and around Pondicherry, South India: A clinical appraisal and prognostic indicators for the outcome. J Trop Pediatr. 2003 Feb; 49(1):48–53. https://doi.org/10.1093/tropje/49.1.48 PMID: 12630721

16. Kumar R, Mathur A, Kumar A, Sharma S, Chakraborty S, Chaturvedi UC. Clinical features and prognostic indicators of Japanese encephalitis in children in Lucknow (India). Indian J Med Res—Sect A Infect Dis [Internet]. 1990 Sep 1 [cited 2022 May 19]; 91(SEPT.) :321–7. Available from: https://europepmc.org/article/med/2176644. PMID: 2176644

17. Libraty DH, Nisalak A, Endy TP, Suntayakorn S, Vaughn DW, Innis BL. Clinical and immunological risk factors for severe disease in Japanese encephalitis. Trans R Soc Trop Med Hyg. 2002; 96(2):173–8. https://doi.org/10.1016/s0035-9203(02)90294-4 PMID: 12055808

18. Kumar R, Mathur A, Singh KB, Sitholey P, Prasad M, Shukla R, Agarwal SP, Arockiasamy J. Clinical sequelae of Japanese encephalitis in children. Indian J Med Res—Sect A Infect Dis. 1993 Jan; 97(JAN.):9–13. PMID: 8387460

19. Kumar R, Tripathi P, Singh S, Bannerji G. Clinical features in children hospitalized during the 2005 epidemic of Japanese encephalitis in Uttar Pradesh, India. Clin Infect Dis. 2006 Jul; 43(2):123–31. https://doi.org/10.1086/505121 PMID: 16779737

20. Rayamajhi A, Ansari I, Ledger E, Bista KP, Impoinville DE, Nightingale S, BC RK, Mahaseth C, Solomon T, Griffiths MJ. Clinical and prognostic features among children with acute encephalitis syndrome in Nepal; a retrospective study. BMC Infect Dis. 2011; 11(1):294. https://doi.org/10.1186/1471-2334-11-294 PMID: 22035278

21. Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: Minutes of a WHO/CVI meeting, Bangkok, Thailand, 13–15 October 1998. Vaccine. 2000 Mar; 18(SUPPL. 2):1–25. https://doi.org/10.1016/s0264-410x(00)00037-2 PMID: 10821969

22. SIMPSON TW, MEIKLEJOHN G. Sequelae of Japanese B encephalitis. Am J Trop Med Hyg. 1947 Nov; 27(6):727–31. PMID: 18897109

23. PIEPER SJ, KURLAND LT. Sequelae of Japanese B and mumps encephalitis: recent follow-up of patients affected in 1947–1948 epidemic on Guam. Am J Trop Med Hyg. 1958; 7(5):481–90. PMID: 13571562

24. Murgod UA, Muthane UB, Ravi V, Radhesh S, Desai A. Persistent movement disorders following Japanese encephalitis. Neurology. 2001 Dec; 57(12):2313–5. https://doi.org/10.1212/wnl.57.12.2313 PMID: 11756619

25. Misra UK, Kalita J. Anterior horn cells are also involved in Japanese encephalitis. Acta Neurol Scand. 1997; 96(2):114–7. https://doi.org/10.1111/j.1600-0404.1997.tb00250.x PMID: 9272188

26. Huy B V., Tu HC, Luan T V., Lindqvist R. Early mental and neurological sequelae after Japanese B encephalitis . Southeast Asian J Trop Med Public Health. 1994; 25(3):549–53. PMID: 7777924

27. Hoke CH, Vaughn DW, Nisalak A, Intralawan P, Poolsupasit S, Jongsawas V, Titsayakorn U, Johnson RT. Effect of High-Dose Dexamethasone on the Outcome of Acute Encephalitis Due to Japanese Encephalitis Virus. J Infect Dis. 1992 Apr; 165(4):631–7. https://doi.org/10.1093/infdis/165.4.631 PMID: 1313068

28. Ding D, Hong Z, Zhao SJ, Clemens JD, Zhou B, Wang B, Huang MS, Zeng J, Guo QH, Liu W, Tao FB, Xu ZY. Long-term disability from acute childhood Japanese encephalitis in Shanghai, China. Am J Trop Med Hyg. 2007; 77(3):528–33. PMID: 17827373

29. Richter RW, Shimojyo S. Neurologic sequelae of Japanese B encephalitis. Neurology. 1961; 11(7):553–9. https://doi.org/10.1212/wnl.11.7.553 PMID: 13741420

30. Benenson MW, Top FH, Gresso W, Ames CW, Altstatt LB. The virulence to man of Japanese encephalitis virus in Thailand. Am J Trop Med Hyg. 1975; 24(6 I):974–80.

31. Bom HS, Kang HK, Joh NJ, Kim SJ, Yoon CM, Cho KK, Park HB. A clinical study of adult Japanese encephalitis in the Chonnam District, Korea, during summer of 1982—a difference between improved and expired cases. Korean J Intern Med. 1986; 1(1):21–5. https://doi.org/10.3904/kjim.1986.1.1.21 PMID: 15759371

32. Han N, Adams J, Fang W, Liu SQ, Rayner S. Investigation of the genotype III to genotype I shift in Japanese encephalitis virus and the impact on human cases. Virol Sin. 2015; 30(4):277–89. https://doi.org/10.1007/s12250-015-3621-4 PMID: 26311492

33. Kab chillan L, Rajendran R, Arunachalam N, Ramesh S, Srinivasan S, Samuel PP, Dash AP. Japanese encephalitis in India: An overview. Indian J Pediatr. 2004; 71(7):609–15. https://doi.org/10.1007/ BF02724120 PMID: 15280610
34. Kyaw AK, Tun MMN, Nabeshima T, Buerano CC, Ando T, Inoue S, Hayasaka D, Lim CK, Saijo M, Thu HM, Thant KZ, Morita K. Japanese encephalitis- and Dengue acute encephalitis syndrome cases in Myanmar. Am J Trop Med Hyg. 2019; 100(3):643–6. https://doi.org/10.4269/ajtmh.18-0530 PMID: 30626568

35. Seo H-J, Kim HC, Klein TA, Ramey AM, Lee J-H, Kyung S-G, Park J-Y, Cho YS, Cho I-S, Yeh J-Y. Molecular Detection and Genotyping of Japanese Encephalitis Virus in Mosquitoes during a 2010 Outbreak in the Republic of Korea. Ooi EE, editor. PLoS One. 2013 Feb; 8(2):e55165. https://doi.org/10.1371/journal.pone.0055165 PMID: 23390520

36. Hazarika NC. Project study on Japanese encephalitis vaccination at Gogamukh, Assam. Vol. 28, Indian pediatrics. 1991. p. 1029–34. PMID: 1666393

37. Tiwari S, Singh RK, Tiwari R, Dhole TN. Japanese encephalitis: A review of the Indian perspective. Brazilian J Infect Dis. 2012 Nov; 16(6):564–73. https://doi.org/10.1016/j.bjid.2012.10.004 PMID: 23141974

38. Heffelfinger JD, Li X, Batmunkh N, Grabovac V, Diorditsa S, Liyanage JB, Patamadilok S, Bahl S, Tiwari S, Singh RK, Tiwari R, Dhole TN. Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease. Vol. 13, Human Vaccines and Immunotherapeutics. Taylor & Francis Inc.; 2017. p. 1320–37.

39. Fischer M, Hills S, Staples E, Johnson B, Yaich M, Solomon T. Japanese Encephalitis Surveillance and Immunization—Asia and Western Pacific Regions, 2012. MMWR Morb Mortal Wkly Rep. 2017 Jun; 66(22):579–83. https://doi.org/10.15585/mmwr.mm6622a3 PMID: 28594790

40. Hu XT, Li QF, Ma C, Zhao ZX, He LF, Tang TT, Yu W, Owiti P. Reduction patterns of Japanese encephalitis incidence following vaccine introduction into long-term expanded program on immunization in Yunnan Province, China. Infect Dis Poverty. 2019 Dec; 8(1):102. https://doi.org/10.1186/s40249-019-0608-7 PMID: 31818328

41. Choe YJ, Taurel A-FF, Nealon J, Seo HS, Kim HS. Systematic review of seroepidemiological studies on Japanese encephalitis in the Republic of Korea. International Journal of Infectious Diseases Elsevier B.V.; Feb, 2018 p. 14–9.

42. Bharucha T, Shearer FM, Vongsavath M, Mayxay M, de Lamballerie X, Newton PN, Zitzmann N, O’Connor Patrick, PhD, Regional Office for South-East Asia; Hombach Joachim, PhD, Wang Susan A., MD, World Health Organization. Hyde Terri, MD, Global Immuniz C. Japanese Encephalitis Surveillance and Immunization—Asia and the Western Pacific, 2012.

43. Hu XT, Li QF, Ma C, Zhao ZX, He LF, Tang TT, Yu W, Owiti P. Reduct ion pattern s of Japanese encephalitis virus infection, and perspectives for future research. Int J Infect Dis. 2020 Jun; 95:444–56. https://doi.org/10.1016/j.ijid.2020.03.039 PMID: 32205287

44. Portnoy A, Jit M, Ferrari M, Hanson M, Brenzel L, Verguet S. Estimates of case-fatality ratios of measles in low-income and middle-income countries: a systematic review and modelling analysis. Lancet Glob Heal. 2019; 7(4):e472–81. https://doi.org/10.1016/s2214-109x(18)30537-0 PMID: 30797735

45. Turtle L, Solomon T. Japanese encephalitis-the prospects for new treatments. Vol. 14, Nature Reviews Neurology. Nature Publishing Group; 2018. p. 298–313.

46. Hegde NR, Gore MM. Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease. Vol. 13, Human Vaccines and Immunotherapeutics. Taylor and Francis Inc.; 2017. p. 1320–37.

47. Portnoy A, Jit M, Ferrari M, Hanson M, Brenzel L, Verguet S. Estimates of case-fatality ratios of measles in low-income and middle-income countries: a systematic review and modelling analysis. Lancet Glob Heal. 2019; 7(4):e472–81. https://doi.org/10.1016/s2214-109x(18)30537-0 PMID: 30797735

48. Vannice KS, Hyde TB, Chu SY, Fox KK, Hills SL, Marfin AA. Japanese Encephalitis Surveillance and Immunization—Asia and Western Pacific, 2012.

49. World Bank Open Data [Internet]. Available from: https://databank.worldbank.org/home.aspx.

50. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; Available from: https://www.r-project.org.

51. Baluni M, Ghildiyal S, Singh D, Himanshu Reddy D, Kumar R, Dhole TN. Increased serum microRNA-29b expression and bad recovery in Japanese encephalitis virus infected patients; A new component to improve the disease recovery. J Neuroimmunol. 2018; 323(July):56–61. https://doi.org/10.1016/j.jneuroim.2018 .07.014 PMID: 30196835

52. Solomon T, Dung NM, Wills B, Kneen R, Gainsborough M, Diet TV, Thuy TTN, Loan HT, Khanh VC, Vaughn DW, White NJ, Farrar JJ. Interferon alfa-2a in Japanese encephalitis: A randomised double-blind placebo-controlled trial. Lancet. 2003; 361(9360):821–6. https://doi.org/10.1016/s0140-6736(03) 12709-2 PMID: 12642049
53. Sarkari NBS, Thacker AK, Barthwal SP, Mishra VK, Prapann S, Srivastava D, Sarkari M. Japanese encephalitis (JE). Part I: Clinical profile of 1,282 adult acute cases of four epidemics. J Neurol. 2012; 259(1):47–57. https://doi.org/10.1007/s00415-011-6118-6 PMID: 21678123

54. Yin Z, Wang X, Li L, Li H, Zhang X, Li J, Ning G, Li F, Liang XQ, Gao L, Liang XX, Li Y. Neurological sequelae of hospitalized Japanese encephalitis cases in Gansu province, China. Am J Trop Med Hyg. 2015; 92(6):1125–9. https://doi.org/10.4269/ajtmh.14-0148 PMID: 25918213

55. Hossain MJ, Gurley ES, Montgomery S, Petersen L, Sejvar J, Fischer M, Panelia A, Powers AM, Nahar N, Uddin AKMR, Rahman ME, Ekram ARMS, Luby SP, Breiman RF. Hospital-based surveillance for Japanese encephalitis at four sites in Bangladesh, 2003–2005. Am J Trop Med Hyg. 2010; 82(2):344–9.

56. Sarkari NBS, Thacker AK, Barthwal SP, Mishra VK, Prapann S, Srivastava D, Sarkari M. Japanese encephalitis (JE) part II: 14 Years’ follow-up of survivors. J Neurol. 2012; 259(1):58–69. https://doi.org/10.1007/s00415-011-6131-9 PMID: 21681633

57. Bhatt GC, Sharma T. Comment on “clinical Profile and Outcome of Japanese Encephalitis in Children Admitted with Acute Encephalitis Syndrome.” Biomed Res Int. 2014;2014(December 2012).

58. Kari K, Liu W, Gautama K, Mammen MP, Clemens JD, Nisalak A, Subrata K, Kim HK, Xu ZY. A hospital-based surveillance for Japanese encephalitis in Bali, Indonesia. BMC Med. 2006; 4:2–8.

59. Takamatsu Y, Uchida L, Nga PT, Okamoto K, Nabeshima T, Thao DTT, Hai DT, Tuyet NT, Duc HM, Luat LX, Hasebe F, Morita K. An approach for differentiating echovirus 30 and Japanese encephalitis virus infections in acute meningitis/encephalitis: A retrospective study of 103 cases in Vietnam. Virol J. 2013; 10:1–9.

60. McNaughton H, Singh A, Khan SA. An outbreak of Japanese encephalitis in a non-endemic region of north-east India. J R Coll Physicians Edinb. 2018; 48(1):25–9. https://doi.org/10.4997/JRCPE.2018.105 PMID: 29741521

61. Baruah HC, Biswas D, Patgiri D, Mahanta J. Clinical outcome and neurological sequelae in serologically confirmed cases of Japanese encephalitis patients in Assam, India. Indian Pediatr. 2002; 39(12):1143–8. PMID: 12522277

62. Ompusunggu S, Hills SL, Maha MS, Moniaga VA, Susilarini NK, Widjaya A, Suswando A, Sedyaningsih ER, Jacobson JA. Confirmatation of Japanese encephalitis as an endemic human disease through sentinel surveillance in Indonesia. Am J Trop Med Hyg. 2008; 79(6):963–70. PMID: 19052312

63. Jain P, Jain A, Kumar A, Prakash S, Khan DK, Garg RK, Kumar R, Arun Kumar G. Epidemiology and etiology of acute encephalitis syndrome in North India. Jpn J Infect Dis. 2014; 67(3):197–203. https://doi.org/10.7883/yoken.67.197 PMID: 24858609

64. Rayamajhi A, Singh R, Prasad R, Khanal B, Singhi S. Clinico-laboratory profile and outcome of Japanese encephalitis in Nepali children. Ann Trop Paediatr. 2006; 26(4):293–301. https://doi.org/10.1179/146532806X152818 PMID: 17132294

65. Misra UK, Kalita J. Movement disorders in Japanese encephalitis. J Neurol. 1997; 244(5):299–303. https://doi.org/10.1007/s004150050090 PMID: 9178154

66. Kalita J, Misra UK, Mani VE, Bhoi SK. Can we differentiate between herpes simplex encephalitis and Japanese encephalitis? J Neurol Sci. 2016; 366:110–5. https://doi.org/10.1016/j.jns.2016.05.017 PMID: 27288787

67. Misra UK, Kalita J. Clinical, radiological and neurophysiological spectrum of JEV encephalitis and other non-specific encephalitis during post-monsoon period in India. Neurol India. 2003; 51(1):55–9. PMID: 12865517

68. Kalita J, Misra UK. EEG in Japanese encephalitis: A clinico-radiological correlation. Electroencephalogr Clin Neurophysiol. 1998; 106(3):238–43. https://doi.org/10.1016/s0013-4694(97)00123-5 PMID: 9743282

69. Kalita J, Misra UK. Markedly severe dystonia in Japanese encephalitis. Mov Disord. 2000; 15(6):1168–72. https://doi.org/10.1002/1531-8257(200011)15:6<1168::aid-mds1016>3.0.co;2-v PMID: 11104201

70. Kalita J, Misra UK. Neurophysiological changes in Japanese encephalitis. Neurol India. 2002; 50(3):262–6. PMID: 12391449

71. Misra UK, Kalita J. Prognosis of Japanese encephalitis patients with dystonia compared to those with parkinsonian features only. Postgrad Med J. 2002; 78(918):238–41. https://doi.org/10.1136/pmj.78.918.238 PMID: 11930028

72. Kalita J, Misra UK, Pandey S, Dhole TN. A Comparison of Clinical and Radiological Findings in Adults and Children with Japanese Encephalitis. Arch Neurol. 2003; 60(12):1760–4. https://doi.org/10.1001/archneur.60.12.1760 PMID: 14676053
89. LI JW, GAO XY, WU Y, FU SH, TAN XJ, CAO YX, ZHANG WH, YIN ZD, HE Y, LI YX, LIANG GD, XU Su Q, Xie ZX, He F, Liu ZC, Song XJ, Zhao FC, Li D, Che FY. Adults with severe Japanese encephalitis: a retrospective analysis of 9 cases in Linyi, China. Neurol Sci. 2020;5–11. https://doi.org/10.1007/s10072-020-04867-8 PMID: 33169192

88. Xiong W, Lu L, Xiao Y, Li J, Zhou D. Mortality and disability due to Japanese encephalitis in elderly adults: Evidence from an adult tertiary care center in west China. Front Neurol. 2019; 10(AUG):1–6. https://doi.org/10.3389/fneur.2019.00918 PMID: 31507521

87. Lopez AL, Raguindin PF, Aldaba JG, Avelino F, Sy AK, Helfelfinger JD, Silva MWT. Epidemiology of Japanese encephalitis in the Philippines prior to routine immunization. Int J Infect Dis. 2021; 102:344–51. https://doi.org/10.1016/j.ijid.2020.09.009 PMID: 33127505

86. Rayamajhi A, Nightingale S, Bhutta NK, Singh R, Ledger E, Bista KP, Lewthwaite P, Mahaseth C, Turtle L, Robinson JS, Galbraith SE, Wnek M, Johnson BW, Faragher B, Griffiths MJ, Solomon T. A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PLoS One. 2015; 10(4).

85. Shoji H, Hiraki Y, Kuwasaki N, Toyomasu T, Kaji M, Okudera T. Japanese encephalitis in the Kurume Hills of Japan, 2002. Jpn J Infect Dis. 2004; 57(2):63–6. PMID: 15118213

84. World Health Organization. Introductory booklet: CBR Guidelines. World Heal Organ. 2010; 1–70.

83. Ayukawa R, Fujimoto H, Ayabe M, Shoji H, Matsui R, Iwata Y, Fukuda H, Ochi K, Noda K, Ono Y, Sakai K, Takehisa Y, Yasui K. An unexpected outbreak of Japanese encephalitis in the Chugoku district of Japan, 2002. Jpn J Infect Dis. 2004; 57(2):63–6. PMID: 15118213

82. Hills SL, Van cuong N, Touch S, Mai HH, Soeung SC, Lien TTH, Samnang C, Sovann L, Van diu P, Tran TQ, Thach MT, See CW, Cardoso J, Solomon T. The epidemiology, clinical features, and long-term prognosis of Japanese encephalitis in central Sarawak, Malaysia, 1997–2005. Clin Infect Dis. 2008 Aug; 47(4):458–68. https://doi.org/10.1086/590008 PMID: 18616397

81. Mong HO, Lewthwaite P, Boon FL, Mohan A, Clear D, Lim L, Krishnan S, Preston T, Chae HC, Phaik FB00314452 PMID: 25479142

80. Misra UK, Kalita J, Srivastava M. Prognosis of Japanese encephalitis: A multivariate analysis. J Neurol Sci. 1998; 161(2):143–7. https://doi.org/10.1016/s0022-510x(98)00265-2 PMID: 9879695

79. Maha MS, Moniaga VA, Hills SL, Widjaya A, Sasmito A, Hariati R, Kupertino Y, Artastra IK, Arifin MZ, Sopian K, Supraptono B, Syarif I, Jacobson JA, Sedyaningsih ER. Outcome and extent of disability following Japanese encephalitis in Indonesian children. Int J Infect Dis. 2009; 13(6):389–93. https://doi.org/10.1016/j.ijid.2009.01.009 PMID: 19346144

78. Rayamajhi A, Nightingale S, Bhatta NK, Singh R, Ledger E, Bista KP, Lewthwaite P, Mahaseth C, Turtle L, Robinson JS, Galbraith SE, Wnek M, Johnson BW, Faragher B, Griffiths MJ, Solomon T. A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PLoS One. 2015; 10(4).

77. Nanishi E, Hoshina T, Sanefuji M, Kadoya R, Kitazawa K, Arahata Y, Sato T, Hirayama Y, Hirai K, Yama M, Nikaido K, Maeda A, Torisu H, Okada K, Sakai Y, Ohga S. A Nationwide Survey of Pediatric-onset Japanese Encephalitis in Japan. Clin Infect Dis. 2019; 68(12):2099–104. https://doi.org/10.1093/cid/ciy816 PMID: 30252025

76. Rayamajhi A, Nightingale S, Bhutta NK, Singh R, Reddy E, Bista KP, Lewthwaite P, Mahaseth C, Turtle L, Robinson JS, Galbraith SE, Wnek M, Johnson BW, Faragher B, Griffiths MJ, Solomon T. A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PLoS One. 2015; 10(4).

75. Pradhan S, Gupta RK, Mathur A. Biphasic illness pattern due to early relapse in Japanese B virus encephalitis. J Neurol Sci. 2001; 183(1):13–8. https://doi.org/10.1016/s0022-510x (00)00453-6 PMID: 11166788

74. Rayamajhi A, Nightingale S, Bhatta NK, Singh R, Ledger E, Bista KP, Lewthwaite P, Mahaseth C, Turtle L, Robinson JS, Galbraith SE, Wnek M, Johnson BW, Faragher B, Griffiths MJ, Solomon T. A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PLoS One. 2015; 10(4).

73. Misra UK, Kalita J, Srivastava M. Prognosis of Japanese encephalitis: A multivariate analysis. J Neurol Sci. 1998; 161(2):143–7. https://doi.org/10.1016/s0022-510x(98)00265-2 PMID: 9879695
91. Sunwoo JS, Lee SKST, Jung KYKH, Park K II, Moon J, Jung KYKH, Kim M, Lee SKST, Chu K. Clinical characteristics of severe Japanese encephalitis: A case series from South Korea. Am J Trop Med Hyg. 2017; 97(2):369–75. https://doi.org/10.4269/ajtmh.17-0054 PMID: 28829730

92. Lo SH, Tang HJ, Lee SSJ, Lee JC, Liu JW, Ko WC, Chang K, Lee CY, Chang YT, Lu PL. Determining the clinical characteristics and prognostic factors for the outcomes of Japanese encephalitis in adults: A multicenter study from southern Taiwan. J Microbiol Immunol Infect. 2019; 52(6):893–901. https://doi.org/10.1016/j.jmii.2019.08.010 PMID: 31628089

93. Tan L Van, Thai LH, Phu NH, Nghia HDT, Chuong L Van, Sinh DX, Phong ND, Mai NTH, Man DNH, Hien VM, Vinh NT, Day J, Chau NNV, Hien TT, Farrar J, de Jong MD, Thwaites G, van Doorn HR, Chau TTH. Viral Aetiology of Central Nervous System Infections in Adults Admitted to a Tertiary Referral Hospital in Southern Vietnam over 12 Years. PLoS Negl Trop Dis. 2014; 8(5). https://doi.org/10.1371/journal.pntd.0003127 PMID: 25165820

94. Basumary LJ, Raja D, Bhuyan D, Das M, Goswami M, Kayal AK. Clinical and radiological spectrum of Japanese encephalitis. J Neurol Sci. 2013; 325(1–2):15–21. https://doi.org/10.1016/j.jns.2012.11.007 PMID: 23260319

95. Solomon T, Dung NM, Kneen R, Thao LTT, Gainsborough M, Nisalak A, Day NPJ, Kirkham FJ, Vaughn DW, Smith S, White NJ. Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis. Brain. 2002; 125(5):1084–93. https://doi.org/10.1093/brain/awf116 PMID: 11960897

96. Griffiths MJ, Lemon J V., Rayamajhi A, Poudel P, Shrestha P, Srivastav V, Kneen R, Medina-Lara A, Singh RR, Solomon T. The Functional, Social and Economic Impact of Acute Encephalitis Syndrome in Nepal—a Longitudinal Follow-Up Study. Zunt JR, editor. PLoS Negl Trop Dis. 2013 Sep; 7(9):17–9. https://doi.org/10.1371/journal.pntd.0002383 PMID: 24069467

97. Yang SE, Pan MJ, Tseng HF, Liau MY. The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine—Results from 30 years experience in Taiwan. Vaccine. 2006 Mar; 24 (14):2669–73. https://doi.org/10.1016/j.vaccine.2005.10.054 PMID: 16314007

98. World Health Organization. Measuring effectiveness and impact of Japanese encephalitis vaccination. World Heal Organ Dep Immunization, Vaccines Biol. 2016;1–45.

99. Hsu LC, Chen YJ, Hsu FK, Huang JH, Chang CM, Chou P, Lin IF, Chang FY. The Incidence of Japanese Encephalitis in Taiwan-A Population-Based Study. PLoS Negl Trop Dis. 2014; 8(7):e3030. https://doi.org/10.1371/journal.pntd.0003030 PMID: 25058573

100. Borah J, Dutta P, Khan SA, Mahanta J. A comparison of clinical features of Japanese encephalitis virus infection in the adult and pediatric age group with Acute Encephalitis Syndrome. J Clin Virol. 2011; 52(1):45–9. https://doi.org/10.1016/j.jcv.2011.06.001 PMID: 21715224